Cardiogen
Preclinical ResearchCardiogen (Ala-Glu-Asp-Arg)
A Khavinson bioregulator peptide targeting cardiac tissue, researched for heart muscle function and cardiovascular aging.
Dose
0.1 - 0.2 mg
Route
Subcutaneous injection
Cycle
10-20 days
Storage
2-8 C (refrigerator) in a dark, dry place, away from light and humidity.
What is Cardiogen?
Cardiogen, a Khavinson bioregulator, is a synthetic tripeptide with the amino acid sequence Lys-Glu-Asp (KED). It is part of a class of peptides hypothesized to possess tissue-specific regulatory functions. Research, primarily in animal models and in vitro studies, suggests Cardiogen's potential role in regulating gene expression and protein synthesis within cardiac tissues, aiming to support cellular homeostasis and function. Its proposed mechanism involves interaction with DNA regulatory regions, influencing cellular processes critical for cardiovascular health. It has been investigated for its potential to modulate age-related changes in the heart and to support recovery following various cardiac stressors in preclinical settings.
Key Benefits
- Cardiac tissue regulation research
🐾 Griffin Says...
Molecular Information
Molecular weight
349.33 g/mol
Length
3 amino acids
Type
Synthetic Peptide Bioregulator
Amino acid sequence
Lys-Glu-Asp (KED)
Cardiogen is a tripeptide bioregulator, often referred to by its amino acid sequence abbreviation KED.
Research Indications
Support of Cardiac Function
Animal studies suggest potential for Cardiogen to support myocardial function and metabolism under various stress conditions (e.g., ischemia-reperfusion, aging-related changes). Evidence: Animal/in-vitro only.
Cellular Homeostasis in Heart Tissue
Preclinical research indicates that Cardiogen may influence gene expression and protein synthesis in cardiac cells, promoting cellular homeostasis. Evidence: Animal/in-vitro only.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Investigating effects on myocardial function in healthy animals | 0.1 mg/kg | Once daily | Subcutaneous |
| Studying age-related cardiac changes in senescent animal models | 0.15 mg/kg | Once daily for 20 days, then monthly | Subcutaneous |
| Assessing protective effects during induced cardiac stress (e.g., ischemia-reperfusion) | 0.2 mg/kg | Once daily, initiated prior to and continued post-stress event | Subcutaneous |
| In vitro studies on cardiomyocyte gene expression | 10-100 nM | Single or multiple applications | Cell culture medium |
Research protocols involving Khavinson bioregulators often involve cyclical administration followed by observation periods.
Peptide Interactions
- Monitor Combination
Other Bioregulator Peptides
Khavinson peptides are often studied in combinations. The effect of Cardiogen with other bioregulators designed for different tissues is not fully understood and requires specific research. Evidence: Animal/in-vitro only.
- Monitor Combination
Standard Cardioprotective Agents
No specific interaction data is available from preclinical research. Co-administration with established cardioprotective agents should be carefully monitored in experimental designs. Evidence: Animal/in-vitro only.
- Use Caution
Anticoagulants
While not directly implicated, any compound affecting cardiovascular systems should be used with caution alongside anticoagulants due to potential unknown synergistic or antagonistic effects. Evidence: Theoretical/Preclinical only.
How to Reconstitute
- 1Gather your lyophilized peptide vial, a sterile syringe, and bacteriostatic water.
- 2Clean the rubber stopper of the peptide vial and the bacteriostatic water vial with alcohol wipes.
- 3Draw the desired amount of bacteriostatic water into the sterile syringe (e.g., 1 ml for 2 mg vial if aiming for 2mg/ml concentration).
- 4Slowly inject the bacteriostatic water into the peptide vial, aiming the stream at the glass wall rather than directly onto the powder.
- 5Remove the syringe and gently swirl the vial for several minutes until the powder is fully dissolved. Do not shake.
- 6Once dissolved, the solution should be clear and colorless. If particles or cloudiness persist, do not use.
Ensure bacteriostatic water is sterile. Use a fresh vial for each reconstitution if possible to avoid contamination. Swirl gently; do not shake vigorously to prevent peptide degradation.
What to Expect
- Lyophilized powder is stable and typically white or off-white.
- Reconstituted solution should be clear and free of particulate matter.
- No immediate acute physiological changes are typically reported in preclinical studies following administration.
- Observations, if any, are generally subtle and require chronic administration in animal models.
- The peptide is administered subcutaneously; minor injection site reactions (e.g., transient redness, discomfort) are possible, as with any injection.
Side Effects & Safety
- Cardiogen is for research purposes only and not for human consumption or therapeutic use.
- Always use sterile techniques for reconstitution and administration to prevent infection.
- Dispose of all needles, syringes, and vials properly in a sharps container.
- Store lyophilized and reconstituted peptides according to recommended temperatures to maintain stability and integrity.
- Researchers should wear appropriate personal protective equipment (PPE) when handling this compound.
- No specific adverse effects or contraindications have been established in human studies, as this is a preclinical research chemical.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.